Accord Logo

Intended for UK patients and members of the public

PIL - Zubsolv 0.7/0.18mg, 1.4/0.36mg, 2.9/0.71mg, 5.7/1.4mg, 8.6/2.1mg, 11.4/2.9mg Sublingual Tablets: Change history

  • To update sections 4.5 and 4.8 of the SmPC to add interactions with gabapentinoids and to add the adverse reaction dental caries with a frequency not known in line with PSUSA/00002113/202309. Consequently, the PIL has been updated.

    • Changes: (Updated: 07 Nov 2024)

      To update sections 4.5 and 4.8 of the SmPC to add interactions with gabapentinoids and to add the adverse reaction dental caries with a frequency not known in line with PSUSA/00002113/202309. Consequently, the PIL has been updated.

    • Changes: (Updated: 02 May 2024)

      Description of update: 'UK only' added to outer packaging to comply with Windsor Framework requirement. Minor typographical amends have been made throughout the Joint PIL.

      PIL sections updated: 2 & 6.

      No changes to SmPC.

    • Changes: (Updated: 27 Apr 2023)

      Website administration update

    • Changes: (Updated: 27 Apr 2023)

      MA holder: Accord Healthcare Limited

       

      Renewal approval date22/03/2023

      (Renewal approval received date – 18/04/2023)

      Renewal submitted date – 04/02/2022

       

      This product is marketed in the UK

       

      An Unlimited MA has been granted, 4 yearly PSURs will be submitted.

       

      SmPC sections updated – 3, 4.1, 4.2, 4.4, 4.5, 4.8, 5.2, 5.3, 6.1, 6.4, 6.5, 9 and 10

    • Changes: (Updated: 16 Mar 2023)

      Variation Description: To update sections 4.4, 4.7, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC to bring in line with the reference product (Suboxone 2 mg/0.5 mg sublingual tablets. Consequently, the PIL has been updated.

      Minor editorial changes have also been made to the PIL.

    • Changes: (Updated: 22 Sep 2022)

      Initial upload

    View product information as a: